Reliance Genemedix Share Discussion Threads

[eriktherock] 04/10/2005 13:31

I don't believe the success of failure of this Business will be affected from the resignation of the CEO. The issues are more fundemental.

[knowing] 04/10/2005 09:25

RNS Number:1373S
GeneMedix PLC
04 October 2005



GENEMEDIX plc

Resignation of CEO

GeneMedix plc today announces the resignation of its Chief Executive Officer,
Paul Edwards, who intends to pursue an alternative business opportunity.

Paul has led GeneMedix plc since 1999 and has built the Company to be one of
the most recognisable names in the field of 'biogenerics'. He will be leaving
the Company at the earliest opportunity, but has expressed a willingness to
assist the Board in finding a successor and to act in a consultancy capacity
in the future.

In the interim, Julian Attfield the Chief Financial Officer will become
Acting CEO. Julian has been with the Company since before its initial public
offering in 2000 and will be working closely with the non-executive Chairman,
Dr Kim Tan and the other non-executives to develop the company's strategic and
corporate activities.

"The Board expresses its thanks to Paul for his services to the company and
wishes him every success in his new career."

Kim Tan, Chairman

[eriktherock] 04/10/2005 09:17

Hi Wiganer, care to elaborate?

[wiganer] 04/10/2005 09:13

GMX left today. Sinking ship, or multi-bagger?

[wiganer] 04/10/2005 09:11

CEO doesn't think so?

[eriktherock] 30/8/2005 00:24

High risk ,yes but multibag potential imo. Bought in @ 12p.

[mr ashley james] 24/7/2005 14:04

ANY GAMING STOCK?

[eriktherock] 06/5/2005 18:44

Recent selling (probably at a massive loss)would suggest that this Company is in the tube and about to go down it. However fortune favours the brave!

[eriktherock] 04/5/2005 18:43

Maybe worth a small investment @ 8p imo,

[eriktherock] 22/4/2005 22:42

Maybe I've overlooked something............No, Partner in the pipeline.

[eriktherock] 14/3/2005 23:09

no longer high risk.

[eriktherock] 05/3/2005 22:41

by my calculations( provided upon kind request) we are looking at a share price of 22p based on current standing. This is high risk of course.

[multisync5] 29/11/2004 09:37

RNS Number:7414F
GeneMedix PLC
29 November 2004



GeneMedix plc

Monomeric Insulin Patent Issued in USA

GeneMedix plc ("GeneMedix" or "the Company"), the UK biopharmaceutical company
with operations in Europe and Asia and with joint London and Singapore Stock
Exchange listings, announces the granting of US Patent 6,800,606 B1 for
monomeric analogues of human insulin.

In line with our forecast in the press release of 19th May 2004, we are pleased
to announce that a U.S. patent has been granted for a novel monomeric insulin.
The fast acting insulin analogue was discovered by scientists at the Shanghai
Institute of Biochemistry and Cell Biology (IBCB), with whom GeneMedix has
agreements to commercialise new technology.

The Company intends to develop the analogue through to completion of Phase I
clinical trials before securing an international partner to complete the
development and commercialisation of the product. There are two fast-acting
insulin analogues currently marketed by Eli Lilly and Novo Nordisk with combined
sales estimated to be in excess of US$1 billion. Analogues are the fastest
growing segment in the US$4.4 billion world insulin market.

Paul Edwards, GeneMedix's Chief Executive Officer, commented:

"Although we had already announced the granting of this patent in Australia, the
confirmation of the U.S. patent grant is significant. The USA is by far the
largest pharmaceutical market in the world, representing over 50% of all product
sales, and recent developments within GeneMedix have been targeted towards the
US market. As we have said before, our potential ability to develop a novel
insulin analogue, together with our on-going development programme for a generic
human insulin, underlines our determination to be a significant player in the
global multi-billion dollar diabetes market."

29th Nov 2004

ENQUIRIES:

GeneMedix plc Tel: [phone]
Paul Edwards, Chief Executive Officer

Bankside Tel: [phone]
Michael Padley
Susan Scott


This information is provided by RNS
The company news service from the London Stock Exchange

END
MSCBLBPTMMJTMMI

[thewrongtime] 28/5/2004 09:23

Does anyone know what's going on with all of these MBB Disclosure announcments from Nomura International? They've been buying and selling almost the same quantity of shares at a time in each disclosure. Until today where they've merely sold.

Any ideas anyone?

Cheers,
J

[amarone] 27/4/2004 09:50

My Dear Handycam,
these guys don't sound like people who stand in the bookies smoking a cigarette all day. GMX have a very good network in the Far East and it looks like TH Group must have undertook some form of due diligence BEFORE making this £360k investment.

IMHO etc,

AMARONE.


KUALA LUMPUR (AFX-ASIA) - TH Group Bhd via its unit THG Capital Sdn Bhd has
invested some 3.8 mln rgt to raise its investments in two companies, South
Korean-based C-Solution Inc Korea and British-based GemeMedix PLC.
Both subscriptions were funded by internally generated funds, TH Group said.
In a statement, the company said THG Capital has subscribed to eight
redeemable convertible bonds worth 1.33 mln rgt in C-Solution.
The group had previously subscribed to 232,500 shares in C-Solution for
10.07 mln rgt or 19.9 pct of post equity interest in the company in April last
year.
C-Solution produces tab ends for beverage makers.
THG Capital has also subscribed to 2.43 mln shares of GeneMedix worth 2.45
mln rgt.
In Nov 29, 2000 TH Group invested 15.3 mln rgt for 3.11 mln shares via
another subsidiary Technology Asia Ventures Sdn Bhd and for 3.0 mln shares via
THG Capital in July last year.
GeneMedix, a biopharmaceutical products company, develops, manufacture and
market a range of products for the treatment of chronic diseases such as cancer.
(1 usd = 3.8 rgt)
[e-mail]
str/lll/mh

[handycam] 26/4/2004 21:16

My Dear Amarone,

I encourage you to believe in the fact that a lot of directors do, actually, tell lies. Goodness knows how they habitually get away with it, but there we are.

Remember also that, just like Turbo Genset, this duff company started life on ofex ( and to ofex it should return) with a market cap of £11m, equivalent to c. 3.5 pence in today's share price. Since that listing they have achieved nothing, apart from pee away a shedload of cash in a similar fashion to Scoot and Bright Station.

I also recall that the gentleman behind the float trousered a bucketload of money from this and other comapnies before they, too, took a very real caning.

You should ask people who paid £2 for this stock and ask them two questions:

1. What on earth made them pick up the phone to part with their cash for GMX? and
2. How do they feel now?

I bet none would average down. In fact, if they are moderately intelligent, they would cut and reverse their long position and quadruple their bet on a CFD bear.

Yours etc.,

Steven

Ps. The placing was not with institutions, more like with Singaporean punters giving the company one last throw of the dice (and all of whom ought to know better). As British people did woth Eurodis and Mayflower.